Loading
RAMP 201 produced the first approved treatment designed for low-grade serous ovarian cancer, a slow-growing type driven by the RAS pathway that shrugs off chemotherapy.
In KRAS-mutant tumours, the confirmed response rate was 44% with median PFS 19.6 months and median duration of response 31.1 months; response was lower in KRAS-wild-type disease (Targeted Oncology, 2025). FDA accelerated approval 8 May 2025 for KRAS-mutated recurrent LGSOC after prior systemic therapy. The confirmatory RAMP 301 phase 3 versus chemotherapy or endocrine therapy is ongoing.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares RAMP 201: avutometinib with or without defactinib in recurrent low-grade serous ovarian cancer, Ovarian cancer.
Shares Verastem Oncology, Ovarian cancer.
Shares Avutometinib + defactinib, KRAS, Ovarian cancer, Small-molecule kinase inhibitors.
Shares Verastem Oncology, Ovarian cancer.
Shares RAMP 201: avutometinib with or without defactinib in recurrent low-grade serous ovarian cancer, Avutometinib + defactinib, Ovarian cancer.
Shares Verastem Oncology, KRAS.
Shares RAS / RAF / MEK / ERK (MAPK), KRAS, Small-molecule kinase inhibitors.
Shares RAS / RAF / MEK / ERK (MAPK), Small-molecule kinase inhibitors.